BI 655066 versus Placebo In a Multicenter Randomized Double-Blind Study in Patients with Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety with Randomized Withdrawal and Re-Treatment (IMMhance)
Aim: The primary objective of this trial are to assess the safety and efficacy of BI 655066 150 mg in comparison to placebo in patients with moderate to severe chronic plaque psoriasis. This study has a 42 day screening period, an 88 week treatment period and a 16 week follow-up period. Patients may be offered an open-label extension study if they have completed the study and meet the inclusion criteria for the open-label study.
Diagnosis: Moderate to Severe Chronic Plaque Psoriasis
Principal Investigator:
Stephanie Mehlis, MD
IRB Approval Number: EH16-060
Sponsor: Boehringer-Ingelheim
Contact: Interested patients should contact research coordinators Barbara Gold, R.N., Judy Spolarich-Kroll or Cristina Fernandez at 847.663.8530
Open to Enrollment: February 2016

Corrona Psoriasis Registry
Aim: 
The primary objective of the Corrona Psoriasis Registry is to study the comparative safety of approved psoriasis therapies in a national cohort of psoriasis subjects treated by dermatologists. This includes assessing the incidence and nature of adverse events and analyzing the epidemilogy and natural history of the disease.
Diagnosis: Psoriasis
Principal Investigator: Stephanie Mehlis, M.D.
IRB Approval Number: EH15-229
Sponsor: Corrona, LLC
Contact: Interested patients should contact research coordinators Barbara Gold, R.N., Judy Spolarich-Kroll or Cristina Fernandez at 847.663.8530
Open to Enrollment: Yes